WA-AMAZON.COM-INC
5.4.2022 13:02:57 CEST | Business Wire | Press release
Amazon (NASDAQ: AMZN) today announced agreements with Arianespace, Blue Origin, and United Launch Alliance (ULA) to provide heavy-lift launch services for Project Kuiper, Amazon’s initiative to increase global broadband access using a constellation of satellites in low Earth orbit (LEO). The contracts total up to 83 launches over a five-year period, providing capacity for Amazon to deploy the majority of its 3,236-satellite constellation. It is the largest commercial procurement of launch vehicles in history.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005519/en/
“Project Kuiper will provide fast, affordable broadband to tens of millions of customers in unserved and underserved communities around the world,” said Dave Limp, Senior Vice President for Amazon Devices & Services. “We still have lots of work ahead, but the team has continued to hit milestone after milestone across every aspect of our satellite system. These launch agreements reflect our incredible commitment and belief in Project Kuiper, and we’re proud to be working with such an impressive lineup of partners to deliver on our mission.”
Project Kuiper aims to provide high-speed, low-latency broadband to a wide range of customers, including individual households, schools, hospitals, businesses, government agencies, disaster relief operations, mobile operators, and other organizations working in places without reliable internet connectivity. Amazon is designing and developing the entire system in-house, combining a constellation of advanced LEO satellites with small, affordable customer terminals and a secure, resilient ground-based communications network. Project Kuiper will leverage Amazon’s global logistics and operations footprint, as well as Amazon Web Services’ (AWS) networking and infrastructure, to serve a diverse, global customer base. Project Kuiper will also apply Amazon’s experience producing low-cost devices and services like Echo and Kindle to deliver service at an affordable, accessible price for customers.
“Securing launch capacity from multiple providers has been a key part of our strategy from day one,” said Rajeev Badyal, Vice President of Technology for Project Kuiper at Amazon. “This approach reduces risk associated with launch vehicle stand-downs and supports competitive long-term pricing for Amazon, producing cost savings that we can pass on to our customers. These large, heavy-lift rockets also mean we can deploy more of our constellation with fewer launches, helping simplify our launch and deployment schedule. We’re excited to move one step closer to connecting residential, business, and government customers around the world.”
The scale of these contracts will also boost the wider launch services industry, driving innovation and job creation in the United States and Europe. Suppliers from 49 U.S. states help develop and manufacture the next-generation, heavy-lift launch vehicles from Blue Origin and ULA, while Arianespace relies on ArianeGroup’s network of suppliers from 13 European countries to produce its Ariane 6 rocket. In addition, Amazon is working with Beyond Gravity (formerly RUAG Space), a Switzerland-headquartered space technology provider, to build low-cost, scalable satellite dispensers that will help deploy the Project Kuiper constellation. Beyond Gravity is opening an all-new production facility as a result of the partnership, doubling its production capacity and creating dozens of jobs in Linköping, Sweden.
Arianespace
Arianespace, the European spaceline, has established itself as a leader in the global launch services industry, completing 15 successful launches last year, including the launch of the James Webb Space Telescope in late December. Arianespace is on its way to start operating its next-generation heavy-lift launch vehicle, Ariane 6, which is scheduled to launch for the first time by the end of this year. Amazon has secured 18 Ariane 6 rockets as part of this initial agreement.
“This contract, the largest we’ve ever signed, is a great moment in Arianespace’s history. We are honored to be given a significant role to play in the deployment of Amazon’s Project Kuiper, which aims to connect tens of millions of people to the internet,” said Stéphane Israël, CEO of Arianespace. “It will build on the European innovative spirit, industrial might, and years of experience, and it is a major win for the European launcher industry. That Amazon has chosen the Ariane 6 to do the job is a matter of tremendous pride for us and a great vote of confidence in our new launch vehicle.”
Blue Origin
Amazon has signed an agreement with Blue Origin to secure 12 launches using New Glenn, with options for up to 15 additional launches. New Glenn is powered by seven BE-4 engines and its reusable first stage is built for a minimum of 25 missions.
“We’re honored to support Amazon’s ambitious mission to provide reliable, affordable broadband to unserved and underserved communities around the world through New Glenn and our BE-4 engines,” said Jarrett Jones, Senior Vice President, New Glenn, Blue Origin. “New Glenn’s seven-meter fairing offers unprecedented mass and volume capabilities, providing Project Kuiper maximum launch flexibility. We also congratulate our partner, United Launch Alliance. We’re proud to build American-made engines for ULA’s Vulcan Centaur.”
United Launch Alliance
Amazon’s agreement with ULA covers 38 launches on Vulcan Centaur, ULA’s newest heavy-lift launch vehicle. This launch services contract also covers production and launch infrastructure to support a higher cadence of launches at Cape Canaveral Space Force Station, including a new, dedicated version of the Vulcan Launch Platform (VLP). ULA is making additional investments in its Spaceflight Processing & Operations Center (SPOC) to deliver a second ULA facility capable of full vehicle processing, transforming the launch site to have two parallel “launch lanes” for high-cadence operations. The agreement is in addition to Project Kuiper’s existing deal to secure nine Atlas V vehicles from ULA.
“This agreement marks the beginning of an exciting new era for ULA and for the entire U.S. launch industry. With a total of 47 launches between our Atlas and Vulcan vehicles, we are proud to launch the majority of this important constellation,” said Tory Bruno, ULA’s president and CEO. “It will support hundreds of jobs, especially in places like Alabama, Colorado and Florida, and Amazon’s investments in launch infrastructure and capability upgrades will benefit both commercial and government customers.”
Project Kuiper plans to launch two prototype missions later this year on ABL Space Systems’ RS1 rocket. There are now more than 1,000 people at Amazon working on Project Kuiper, and the team continues to make progress as it approaches a full, production-ready deployment—finalizing its high-performance satellite design, producing a compact, affordable customer terminal, and deploying a secure, reliable communications network that connects satellites to customers and infrastructure on the ground. Once deployed, the Kuiper System will have the capacity to serve tens of millions of residential, business, and government customers in places without reliable broadband. Moving forward, Amazon will continue to partner with companies that share its commitment to closing the global digital divide and creating new opportunities for innovation. To learn more about Project Kuiper, watch our overview video .
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding anticipated business activities, made in this press release are forward-looking. We use words such as aims, anticipates, believes, expects, future, intends, will, and similar expressions to identify forward-looking statements. Forward-looking statements reflect management’s current expectations and are inherently uncertain. Actual results and outcomes could differ materially for a variety of reasons, including, among others, changes in our liquidity, financial condition, or capital allocation and financing strategies or in the debt and equity markets, including as a result of fluctuations in foreign exchange rates, changes in global economic conditions and customer spending, world events, the rate of growth of the Internet, online commerce, and cloud services, the amount that Amazon.com invests in new business opportunities and the timing of those investments, the mix of products and services sold to customers, the mix of net sales derived from products as compared with services, the extent to which we owe income or other taxes, competition, management of growth, potential fluctuations in operating results, international growth and expansion, the outcomes of claims, litigation, government investigations, and other proceedings, fulfillment, sortation, delivery, and data center optimization, risks of inventory management, variability in demand, the degree to which we enter into, maintain, and develop commercial agreements, proposed and completed acquisitions and strategic transactions, payments risks, and risks of fulfillment throughput and productivity. In addition, the global economic climate and additional or unforeseen effects from the global pandemic amplify many of these risks. These risks and uncertainties, as well as other risks and uncertainties that could cause our actual results to differ significantly from management’s expectations, are described in greater detail in Amazon.com’s filings with the Securities and Exchange Commission (“SEC”), including its most recent Annual Report on Form 10-K and subsequent filings. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, you are advised to consult any additional disclosures we make in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005519/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
